These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1507 related items for PubMed ID: 29059433

  • 21. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX.
    Breast Cancer Res Treat; 2011 Jul; 128(2):347-56. PubMed ID: 20730488
    [Abstract] [Full Text] [Related]

  • 22. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
    Clin Cancer Res; 2009 Jun 15; 15(12):4147-56. PubMed ID: 19509167
    [Abstract] [Full Text] [Related]

  • 23. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
    Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J.
    Clin Cancer Res; 2017 Nov 15; 23(22):7006-7019. PubMed ID: 28821558
    [Abstract] [Full Text] [Related]

  • 24. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T, Truesdell P, Craig AW.
    Breast Cancer Res; 2017 Oct 03; 19(1):110. PubMed ID: 28974266
    [Abstract] [Full Text] [Related]

  • 25. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.
    Mol Cancer Ther; 2012 Sep 03; 11(9):1978-87. PubMed ID: 22761403
    [Abstract] [Full Text] [Related]

  • 26. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.
    Curr Med Res Opin; 2013 Apr 03; 29(4):405-14. PubMed ID: 23402224
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar 03; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S, Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S, Şahin Ö.
    Oncogene; 2018 Apr 03; 37(17):2251-2269. PubMed ID: 29391599
    [Abstract] [Full Text] [Related]

  • 31. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
    Al-Saden N, Lam K, Chan C, Reilly RM.
    Mol Pharm; 2018 Aug 06; 15(8):3383-3393. PubMed ID: 29957952
    [Abstract] [Full Text] [Related]

  • 32. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.
    Breast Cancer Res; 2011 Aug 31; 13(4):R84. PubMed ID: 21884573
    [Abstract] [Full Text] [Related]

  • 33. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
    Cancer Med; 2014 Oct 31; 3(5):1256-65. PubMed ID: 24890382
    [Abstract] [Full Text] [Related]

  • 34. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD.
    Clin Cancer Res; 2016 Aug 01; 22(15):3755-63. PubMed ID: 26920887
    [Abstract] [Full Text] [Related]

  • 35. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
    Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.
    J Natl Cancer Inst; 2007 May 02; 99(9):694-705. PubMed ID: 17470737
    [Abstract] [Full Text] [Related]

  • 36. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy.
    Massicano AVF, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE.
    Cancer Biother Radiopharm; 2019 May 02; 34(4):209-217. PubMed ID: 30676778
    [Abstract] [Full Text] [Related]

  • 37. Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.
    Sun Y, Dey N, Brammer M, De P, Leyland-Jones B.
    Cancer Chemother Pharmacol; 2013 Oct 02; 72(4):733-45. PubMed ID: 23959459
    [Abstract] [Full Text] [Related]

  • 38. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I, Winer EP.
    Clin Cancer Res; 2014 Jan 01; 20(1):15-20. PubMed ID: 24135146
    [Abstract] [Full Text] [Related]

  • 39. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 01; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 40. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
    Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.
    Cancer Res; 2017 Sep 01; 77(17):4639-4651. PubMed ID: 28687619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 76.